Skip to content

Market explorer

Screen the results we have checked

Search and filter our published results. This is selected coverage, not a screen of every listed stock.

Read the basis before comparing. Revenue is the company's reported revenue line, not a standardised comparable measure. Excise, acquisitions, exceptional items and different reporting periods can change growth. Missing revenue or growth is not zero. Each result below keeps its filing basis and caveats. No live prices, valuation filters or recommendations.

1 matching results out of 156 published entries. 69 have revenue growth available.

Dr. Reddy's Laboratories

-1.53% revenue YoY

Q2 FY2027 · Period ended 30 Sep 2026

Basis: Consolidated, IFRS, as presented in the company's press release

Reported revenue (₹ million): 86,708

Read summary and comparison caveats

Dr. Reddy's reported September-quarter revenues of ₹86,708 million, down 1.5% year on year and up 7.4% on the June quarter. Profit attributable to equity holders was ₹9,250 million, down 36% year on year and more than double the June quarter.

  • Source: the consolidated income statement in Dr. Reddy's Q2 and H1 FY27 press release dated 23 Oct 2026, from the company's own website. Values are in ₹ million. Year ago is Q2 FY26; previous quarter is Q1 FY27. Percentage changes are computed from the printed values.
  • The company says the figures are based on consolidated financial statements under IFRS, which can differ from the Ind AS presentation used by most companies on this page. The company's note says Q1 FY27 results were impacted by a ₹2,397 million provision related to semaglutide API, which affects the quarter-on-quarter comparison.
  • EBITDA is the company's own computation, shown in the release. We did not read the audit or review status.
  • This page is a selected set of checked results, not complete market coverage.

Checked 2 Nov 2026

Open original filing
Read the complete published results desk